- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Alexion Pharmaceuticals (Nasdaq: ALXN) hit a new 52-week high Wednesday as it is currently trading at $117.69, above its previous 52-week high of $117.65 with 647,079 shares traded as of 3:40 p.m. ET. Average volume has been 1.2 million shares over the past 30 days. Alexion has a market cap of $22.39 billion and is part of the health care sector and drugs industry. Shares are up 63.1% year to date as of the close of trading on Tuesday. Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company has a P/E ratio of 114.9, below the average drugs industry P/E ratio of 116 and above the S&P 500 P/E ratio of 17.7.